Association of gamma- -glutamyltranspeptidase and uric acid with anthropometric indices and metabolic risk factors in women with excessive body weight — a preliminary study

Introduction. Obesity is strongly associated with insulin resistance, known to be related to elevated gamma-glutamyltranspeptidase activity (GGTP) and uric acid (UA) level. However, the mechanism of this relationship has not yet been clarified. We investigated the relationship of GGTP and UA with anthropometry and components of metabolic syndrome in overweight and obese young women.Materials and methods. GGTP, UA, fasting glucose, fasting insulin, HOMA and lipids were determined inblood samples obtained from overweight (n = 24; BMI = 25–30 kg/m2) and obese (n = 28; BMI > 30 kg/m2) women aged 25–40 yrs and age-matched healthy controls (n = 38; BMI < 25 kg/m2).Results. GGTP and UA were elevated over the upper reference values only in 19.2% and 11.5% of women from the study group, but median GGTP and UA were significantly higher in obese and overweight women compared to controls. In the whole study group, and in obese women, GGTP activity was more associated with WC, WHR and WtHR which was not found for UA. The correlations between GGTP and HOMA-IR and fasting insulin were significant for women with excessive body weight and obese women only, whereas the correlations between UA and parameters of insulin resistance in the whole study group and in obesity did not reach statistical significance. Moreover, we found significant differences in GGTP activity between women with and without insulin resistance in both the study group and obese women(p < 0.0001; p < 0.01). In the whole study group, and in obese women only, GGTP positively correlated with TC, LDL-C, TG, TC/HDL-C ratio, SBP and DBP, whereas in overweight women it only correlated with SBP. We also found that women in higher GGTP quartiles had higher concentrations of TC, LDL-C andTC/HDL-C ratio (p < 0.03; p < 0.05; p < 0.05 for quartile trend respectively).Conclusions. GGTP activity and uric acid concentration are higher in overweight and obese women, although only GGTP activity seems to be related to anthropometric parameters, insulin resistance and atherogenic indices, essential components of metabolic syndrome in young women. GGTP activity maybe a surrogate marker of insulin resistance and metabolic syndrome

Serum Anti-Müllerian Hormone Levels in Patients with Epithelial Ovarian Cancer

Objectives. The aim of our study was to examine serum anti-Müllerian hormone (AMH) concentration in ovarian cancer patients in relation to clinicopathological features, such as a pathological subtype of the tumor, (FIGO) stage, grading, and overall 5-year survival. Material and Methods. We enrolled 72 epithelial ovarian cancer patients in our study, aged 45–79 years, who underwent optimal cytoreductive surgery. In all patients, serum AMH concentration was measured using a two-step sandwich type enzyme immunoassay before surgery. As a reference value for women over 45 years we accepted anti-Müllerian hormone concentration below 1 ng/mL. Results. In the whole group of patients with ovarian cancer, median serum concentration of AMH was 0.07 (0.0–0.37) ng/mL, whereas in the group of those with positive AMH values (≥0.14 ng/mL) it was 0.31 (0.15–0.73) ng/mL. No significant correlation was found between serum AMH levels and FIGO stage, histological subtype, or grading (). The analysis of five-year survival rate related to AMH levels showed no statistically significant differences. There were no differences in survival rates between patients with positive or negative serum AMH levels. Conclusion. Measurement of serum anti-Müllerian hormone levels was not useful in predicting clinicopathological features and survival in patients with ovarian cancer

Survival curves in relation to inhibin B levels (p = 0,00625, log-rank test).

<p>Survival curves in relation to inhibin B levels (p = 0,00625, log-rank test).</p

Prediction of death within five years for the variable inhibin B (pg/mL).

<p>Prediction of death within five years for the variable inhibin B (pg/mL).</p

The diagnostic value of age and inhibin A and B for the prediction of death within five years.

<p>The diagnostic value of age and inhibin A and B for the prediction of death within five years.</p

Inhibin A and Inhibin B concentrations in relation to FIGO stage.

<p>FIGO stage- the International Federation of Gynecology and Obstetrics stage; Q1: lower quartile; Q2: median; Q3: upper quartile.</p

Survival curves in relation to inhibin A levels (p = 0,46, log-rank test).

<p>Survival curves in relation to inhibin A levels (p = 0,46, log-rank test).</p

Inhibin A and inhibin B concentrations in relation to the histological type of cancer.

<p>Q1: lower quartile; Q2: median; Q3: upper quartile.</p

Baseline characteristics of the study group.

<p>Baseline characteristics of the study group.</p